Drugs / ADXS-NEO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03265080 | Mar 2018 → Oct 2019 | head and neck cancer, metastasis from malignant tumor of colon, metastatic melanoma, non-small cell lung carcinoma +1 | Advaxis, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADXS-NEO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03265080 ↗ |
| Modality | Vaccine | “The development of a Listeria monocytogenes (Lm)-based vaccine that expresses these participant-specific tumor antigens and that activates tumor-killing T cells has the...” NCT03265080 ↗ |
| Route | Intravenous | “Intravenous infusion” NCT03265080 ↗ |